Genetic approaches to the treatment of inherited neuromuscular diseases

Bhavya Ravi, Anthony Antonellis, Charlotte J. Sumner, Andrew P. Lieberman

Research output: Contribution to journalReview article

Abstract

Inherited neuromuscular diseases are a heterogeneous group of developmental and degenerative disorders that affect motor unit function. Major challenges toward developing therapies for these diseases include heterogeneity with respect to clinical severity, age of onset and the primary cell type that is affected (e.g. motor neurons, skeletal muscle and Schwann cells). Here, we review recent progress toward the establishment of genetic therapies to treat inherited neuromuscular disorders that affect both children and adults with a focus on spinal muscular atrophy, Charcot-Marie-Tooth disease and spinal and bulbar muscular atrophy. We discuss clinical features, causative mutations and emerging approaches that are undergoing testing in preclinical models and in patients or that have received recent approval for clinical use. Many of these efforts employ antisense oligonucleotides to alter pre-mRNA splicing or diminish target gene expression and use viral vectors to replace expression of mutant genes. Finally, we discuss remaining challenges for optimizing the delivery and effectiveness of these approaches. In sum, therapeutic strategies for neuromuscular diseases have shown encouraging results, raising hope that recent strides will translate into significant clinical benefits for patients with these disorders.

Original languageEnglish (US)
Pages (from-to)R55-R64
JournalHuman molecular genetics
Volume28
Issue numberR1
DOIs
StatePublished - Oct 1 2019

Fingerprint

Neuromuscular Diseases
Atrophic Muscular Disorders
Charcot-Marie-Tooth Disease
Gene Expression
Spinal Muscular Atrophy
Antisense Oligonucleotides
Schwann Cells
RNA Precursors
Motor Neurons
Age of Onset
Genetic Therapy
Muscle Cells
Skeletal Muscle
Mutation
Therapeutics
Motor Disorders

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Genetic approaches to the treatment of inherited neuromuscular diseases. / Ravi, Bhavya; Antonellis, Anthony; Sumner, Charlotte J.; Lieberman, Andrew P.

In: Human molecular genetics, Vol. 28, No. R1, 01.10.2019, p. R55-R64.

Research output: Contribution to journalReview article

Ravi, Bhavya ; Antonellis, Anthony ; Sumner, Charlotte J. ; Lieberman, Andrew P. / Genetic approaches to the treatment of inherited neuromuscular diseases. In: Human molecular genetics. 2019 ; Vol. 28, No. R1. pp. R55-R64.
@article{83b93bef983b42718d796ab1e5d97306,
title = "Genetic approaches to the treatment of inherited neuromuscular diseases",
abstract = "Inherited neuromuscular diseases are a heterogeneous group of developmental and degenerative disorders that affect motor unit function. Major challenges toward developing therapies for these diseases include heterogeneity with respect to clinical severity, age of onset and the primary cell type that is affected (e.g. motor neurons, skeletal muscle and Schwann cells). Here, we review recent progress toward the establishment of genetic therapies to treat inherited neuromuscular disorders that affect both children and adults with a focus on spinal muscular atrophy, Charcot-Marie-Tooth disease and spinal and bulbar muscular atrophy. We discuss clinical features, causative mutations and emerging approaches that are undergoing testing in preclinical models and in patients or that have received recent approval for clinical use. Many of these efforts employ antisense oligonucleotides to alter pre-mRNA splicing or diminish target gene expression and use viral vectors to replace expression of mutant genes. Finally, we discuss remaining challenges for optimizing the delivery and effectiveness of these approaches. In sum, therapeutic strategies for neuromuscular diseases have shown encouraging results, raising hope that recent strides will translate into significant clinical benefits for patients with these disorders.",
author = "Bhavya Ravi and Anthony Antonellis and Sumner, {Charlotte J.} and Lieberman, {Andrew P.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1093/hmg/ddz131",
language = "English (US)",
volume = "28",
pages = "R55--R64",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "R1",

}

TY - JOUR

T1 - Genetic approaches to the treatment of inherited neuromuscular diseases

AU - Ravi, Bhavya

AU - Antonellis, Anthony

AU - Sumner, Charlotte J.

AU - Lieberman, Andrew P.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Inherited neuromuscular diseases are a heterogeneous group of developmental and degenerative disorders that affect motor unit function. Major challenges toward developing therapies for these diseases include heterogeneity with respect to clinical severity, age of onset and the primary cell type that is affected (e.g. motor neurons, skeletal muscle and Schwann cells). Here, we review recent progress toward the establishment of genetic therapies to treat inherited neuromuscular disorders that affect both children and adults with a focus on spinal muscular atrophy, Charcot-Marie-Tooth disease and spinal and bulbar muscular atrophy. We discuss clinical features, causative mutations and emerging approaches that are undergoing testing in preclinical models and in patients or that have received recent approval for clinical use. Many of these efforts employ antisense oligonucleotides to alter pre-mRNA splicing or diminish target gene expression and use viral vectors to replace expression of mutant genes. Finally, we discuss remaining challenges for optimizing the delivery and effectiveness of these approaches. In sum, therapeutic strategies for neuromuscular diseases have shown encouraging results, raising hope that recent strides will translate into significant clinical benefits for patients with these disorders.

AB - Inherited neuromuscular diseases are a heterogeneous group of developmental and degenerative disorders that affect motor unit function. Major challenges toward developing therapies for these diseases include heterogeneity with respect to clinical severity, age of onset and the primary cell type that is affected (e.g. motor neurons, skeletal muscle and Schwann cells). Here, we review recent progress toward the establishment of genetic therapies to treat inherited neuromuscular disorders that affect both children and adults with a focus on spinal muscular atrophy, Charcot-Marie-Tooth disease and spinal and bulbar muscular atrophy. We discuss clinical features, causative mutations and emerging approaches that are undergoing testing in preclinical models and in patients or that have received recent approval for clinical use. Many of these efforts employ antisense oligonucleotides to alter pre-mRNA splicing or diminish target gene expression and use viral vectors to replace expression of mutant genes. Finally, we discuss remaining challenges for optimizing the delivery and effectiveness of these approaches. In sum, therapeutic strategies for neuromuscular diseases have shown encouraging results, raising hope that recent strides will translate into significant clinical benefits for patients with these disorders.

UR - http://www.scopus.com/inward/record.url?scp=85073584722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073584722&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddz131

DO - 10.1093/hmg/ddz131

M3 - Review article

C2 - 31227836

AN - SCOPUS:85073584722

VL - 28

SP - R55-R64

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - R1

ER -